{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T06:11:58Z","timestamp":1793427118140,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11523-025-01188-8","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T10:03:48Z","timestamp":1764756228000},"page":"23-35","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Can PARP Inhibitors Benefit Patients with Homologous Recombination Repair-Proficient Castration-Resistant Prostate Cancer? A Meta-analysis"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5653-999X","authenticated-orcid":false,"given":"Susu","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devashish","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che-Kai","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"1188_CR1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.15382.1","volume":"7","author":"C Ritch","year":"2018","unstructured":"Ritch C, Cookson M. Recent trends in the management of advanced prostate cancer. F1000Res. 2018;7:F1000 Faculty Rev-1513. https:\/\/doi.org\/10.12688\/f1000research.15382.1.","journal-title":"F1000Res"},{"key":"1188_CR2","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1080\/14656566.2023.2244415","volume":"24","author":"M Mitsogianni","year":"2023","unstructured":"Mitsogianni M, Papatsoris A, Bala VM, Issa H, Moussa M, Mitsogiannis I. An overview of hormonal directed pharmacotherapy for the treatment of prostate cancer. Expert Opin Pharmacother. 2023;24:1765\u201374. https:\/\/doi.org\/10.1080\/14656566.2023.2244415.","journal-title":"Expert Opin Pharmacother"},{"key":"1188_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102096","volume":"22","author":"F Paolieri","year":"2024","unstructured":"Paolieri F, Sammarco E, Ferrari M, Salfi A, Bonato A, Serafin D, et al. Front-line therapeutic strategy in metastatic hormone sensitive prostate cancer: an updated therapeutic algorithm. Clin Genitourin Cancer. 2024;22:102096. https:\/\/doi.org\/10.1016\/j.clgc.2024.102096.","journal-title":"Clin Genitourin Cancer"},{"key":"1188_CR4","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/14737140.2023.2207827","volume":"23","author":"G Nuvola","year":"2023","unstructured":"Nuvola G, Santoni M, Rizzo M, Rosellini M, Mollica V, Rizzo A, et al. Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer. Expert Rev Anticancer Ther. 2023;23:593\u2013600. https:\/\/doi.org\/10.1080\/14737140.2023.2207827.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1188_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.20517\/cdr.2024.173","volume":"8","author":"A Khorasanchi","year":"2025","unstructured":"Khorasanchi A, Hong F, Yang Y, Singer EA, Wang P, Li M, et al. Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches. Cancer Drug Resist. 2025;8:9. https:\/\/doi.org\/10.20517\/cdr.2024.173.","journal-title":"Cancer Drug Resist."},{"key":"1188_CR6","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrm1963","volume":"7","author":"V Schreiber","year":"2006","unstructured":"Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol. 2006;7:517\u201328. https:\/\/doi.org\/10.1038\/nrm1963.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1188_CR7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrm3376","volume":"13","author":"BA Gibson","year":"2012","unstructured":"Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol. 2012;13:411\u201324. https:\/\/doi.org\/10.1038\/nrm3376.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1188_CR8","unstructured":"U.S. Food and Drug Administration. FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer. Accessed 5 Jan 2023."},{"key":"1188_CR9","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer. Accessed 5 Jan 2023."},{"key":"1188_CR10","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41467-017-00393-y","volume":"8","author":"M Asim","year":"2017","unstructured":"Asim M, Tarish F, Zecchini HI, Sanjiv K, Gelali E, Massie CE, et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun. 2017;8:374. https:\/\/doi.org\/10.1038\/s41467-017-00393-y.","journal-title":"Nat Commun"},{"key":"1188_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aam7479","volume":"10","author":"L Li","year":"2017","unstructured":"Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, et al. Androgen receptor inhibitor-induced \u201cBRCAness\u201d and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal. 2017;10:eaam7479. https:\/\/doi.org\/10.1126\/scisignal.aam7479.","journal-title":"Sci Signal"},{"key":"1188_CR12","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1200\/JCO.22.01649","volume":"41","author":"KN Chi","year":"2023","unstructured":"Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, et al. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. J Clin Oncol. 2023;41:3339\u201351. https:\/\/doi.org\/10.1200\/JCO.22.01649.","journal-title":"J Clin Oncol"},{"key":"1188_CR13","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200043","volume":"1","author":"NW Clarke","year":"2022","unstructured":"Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Loredo E, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 2022;1:EVIDoa2200043. https:\/\/doi.org\/10.1056\/EVIDoa2200043.","journal-title":"NEJM Evid"},{"key":"1188_CR14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","volume":"402","author":"N Agarwal","year":"2023","unstructured":"Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023;402:291\u2013303. https:\/\/doi.org\/10.1016\/S0140-6736(23)01055-3.","journal-title":"Lancet"},{"key":"1188_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. https:\/\/doi.org\/10.1136\/bmj.n160.","journal-title":"BMJ"},{"key":"1188_CR16","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73:712\u20136. https:\/\/doi.org\/10.1046\/j.1445-2197.2003.02748.x.","journal-title":"ANZ J Surg"},{"key":"1188_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928.","journal-title":"BMJ"},{"key":"1188_CR18","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s11523-024-01073-w","volume":"19","author":"S Zhou","year":"2024","unstructured":"Zhou S, Kishi N, Alerasool P, Rohs NC. Adverse event profile of epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer: an updated meta-analysis. Target Oncol. 2024;19:547\u201364. https:\/\/doi.org\/10.1007\/s11523-024-01073-w.","journal-title":"Target Oncol"},{"key":"1188_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/jep.14138","volume":"3","author":"I Elmakaty","year":"2025","unstructured":"Elmakaty I. Mastering meta-analysis in Microsoft Excel with MetaXL add-in: a comprehensive tutorial and guide to meta-analysis. J Eval Clin Pract. 2025;3:e14138. https:\/\/doi.org\/10.1111\/jep.14138.","journal-title":"J Eval Clin Pract"},{"key":"1188_CR20","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.cegh.2018.05.005","volume":"7","author":"M Richardson","year":"2019","unstructured":"Richardson M, Garner P, Donegan S. Interpretation of subgroup analyses in systematic reviews: a tutorial. Clin Epidemiol Glob Health. 2019;7:192\u20138. https:\/\/doi.org\/10.1016\/j.cegh.2018.05.005.","journal-title":"Clin Epidemiol Glob Health"},{"issue":"5","key":"1188_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkad069","volume":"7","author":"Y Suzuki","year":"2023","unstructured":"Suzuki Y, Zhou S, Ota Y, Harrington M, Miyagi E, Takagi H, et al. Toxicity profiles of antibody-drug conjugates for anticancer treatment: a systematic review and meta-analysis. JNCI Cancer Spectr. 2023;7(5):pkad069. https:\/\/doi.org\/10.1093\/jncics\/pkad069.","journal-title":"JNCI Cancer Spectr"},{"key":"1188_CR22","unstructured":"Review Manager (RevMan) [Computer program] Version 5.4 TCC. 2020."},{"key":"1188_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102066","volume":"22","author":"S Zhou","year":"2024","unstructured":"Zhou S, Alerasool P, Kishi N, Joshi H, Sahni G, Tsao CK. Cardiovascular toxicity associated with androgen receptor axis-targeted agents in patients with prostate cancer: a meta-analysis of randomized controlled trials. Clin Genitourin Cancer. 2024;22:102066. https:\/\/doi.org\/10.1016\/j.clgc.2024.102066.","journal-title":"Clin Genitourin Cancer"},{"key":"1188_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004761","volume":"10","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Retz M, Petrylak DP, Goh JC, Perez-Gracia J, Lacombe L, et al. Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial. J Immunother Cancer. 2022;10:e004761. https:\/\/doi.org\/10.1136\/jitc-2022-004761.","journal-title":"J Immunother Cancer"},{"key":"1188_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0463-2","volume":"6","author":"F Karzai","year":"2018","unstructured":"Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A, et al. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J Immunother Cancer. 2018;6:141. https:\/\/doi.org\/10.1186\/s40425-018-0463-2.","journal-title":"J Immunother Cancer"},{"key":"1188_CR26","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373:1697\u2013708. https:\/\/doi.org\/10.1056\/NEJMoa1506859.","journal-title":"N Engl J Med"},{"key":"1188_CR27","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1158\/1078-0432.CCR-22-2585","volume":"29","author":"D Pook","year":"2023","unstructured":"Pook D, Geynisman DM, Carles J, de Braud F, Joshua AM, P\u00e9rez-Gracia JL, et al. A phase Ib, open-label study evaluating the safety and efficacy of Ipatasertib plus Rucaparib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2023;29:3292\u2013300. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2585.","journal-title":"Clin Cancer Res"},{"key":"1188_CR28","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41391-022-00636-0","volume":"26","author":"MT Schweizer","year":"2023","unstructured":"Schweizer MT, Gulati R, Yezefski T, Cheng HH, Mostaghel E, Haffner MC, et al. Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2023;26:194\u2013200. https:\/\/doi.org\/10.1038\/s41391-022-00636-0.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1188_CR29","doi-asserted-by":"publisher","DOI":"10.1200\/PO-25-00457","volume":"9","author":"I Tsung","year":"2025","unstructured":"Tsung I, Smith DC, Heath EI, Cackowski F, Devitt ME, Braun TM, et al. Multicenter phase II study of olaparib and the ATR inhibitor ceralasertib in metastatic castration-resistant prostate cancer (TRAP). JCO Precis Oncol. 2025;9:e2500457. https:\/\/doi.org\/10.1200\/PO-25-00457.","journal-title":"JCO Precis Oncol"},{"key":"1188_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.eururo.2022.08.005","volume":"83","author":"EY Yu","year":"2023","unstructured":"Yu EY, Piulats JM, Gravis G, Fong PCC, Todenh\u00f6fer T, Laguerre B, et al. Pembrolizumab plus Olaparib in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b\/2 KEYNOTE-365 cohort A study. Eur Urol. 2023;83:15\u201326. https:\/\/doi.org\/10.1016\/j.eururo.2022.08.005.","journal-title":"Eur Urol"},{"key":"1188_CR31","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(25)00684-1","volume":"406","author":"N Agarwal","year":"2025","unstructured":"Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Szczylik C, et al. Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet. 2025;406:447\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(25)00684-1.","journal-title":"Lancet"},{"key":"1188_CR32","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","volume":"19","author":"N Clarke","year":"2018","unstructured":"Clarke N, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2018;19:975\u201386. https:\/\/doi.org\/10.1016\/S1470-2045(18)30365-6.","journal-title":"Lancet Oncol"},{"key":"1188_CR33","doi-asserted-by":"publisher","first-page":"5830","DOI":"10.3390\/cancers13225830","volume":"13","author":"TH Carr","year":"2021","unstructured":"Carr TH, Adelman C, Barnicle A, Kozarewa I, Luke S, Lai Z, et al. Homologous recombination repair gene mutation characterization by liquid biopsy: a phase II trial of olaparib and abiraterone in metastatic castrate-resistant prostate cancer. Cancers (Basel). 2021;13:5830. https:\/\/doi.org\/10.3390\/cancers13225830.","journal-title":"Cancers (Basel)"},{"key":"1188_CR34","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","volume":"24","author":"F Saad","year":"2023","unstructured":"Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1094\u2013108. https:\/\/doi.org\/10.1016\/S1470-2045(23)00382-0.","journal-title":"Lancet Oncol"},{"key":"1188_CR35","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1200\/JCO.2017.75.7310","volume":"36","author":"M Hussain","year":"2018","unstructured":"Hussain M, Daignault-Newton S, Twardowski PW, Albany C, Stein MN, Kunju LP, et al. Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012. J Clin Oncol. 2018;36:991\u20139. https:\/\/doi.org\/10.1200\/JCO.2017.75.7310.","journal-title":"J Clin Oncol"},{"key":"1188_CR36","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1200\/JCO.21.02947","volume":"41","author":"JW Kim","year":"2023","unstructured":"Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, et al. Randomized trial of olaparib with or without cediranib for metastatic castration-resistant prostate cancer: the results from National Cancer Institute 9984. J Clin Oncol. 2023;41:871\u201380. https:\/\/doi.org\/10.1200\/JCO.21.02947.","journal-title":"J Clin Oncol"},{"key":"1188_CR37","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1200\/JCO.2025.43.16_suppl.5007","volume":"43","author":"R McKay","year":"2025","unstructured":"McKay R, Xie W, Ajmera A, Jamieson C, Araneta A, Folefac E, et al. A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis. J Clin Oncol. 2025;43(16_Suppl):5007. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.5007.","journal-title":"J Clin Oncol"},{"key":"1188_CR38","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1158\/2159-8290.CD-12-0120","volume":"2","author":"MJ Schiewer","year":"2012","unstructured":"Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov. 2012;2:1134\u201349. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0120.","journal-title":"Cancer Discov"},{"key":"1188_CR39","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/1541-7786.MCR-13-0672","volume":"12","author":"MJ Schiewer","year":"2014","unstructured":"Schiewer MJ, Knudsen KE. Transcriptional roles of PARP1 in cancer. Mol Cancer Res. 2014;12:1069\u201380. https:\/\/doi.org\/10.1158\/1541-7786.MCR-13-0672.","journal-title":"Mol Cancer Res"},{"key":"1188_CR40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.molcel.2010.06.017","volume":"39","author":"R Krishnakumar","year":"2010","unstructured":"Krishnakumar R, Kraus WL. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell. 2010;39:8\u201324. https:\/\/doi.org\/10.1016\/j.molcel.2010.06.017.","journal-title":"Mol Cell"},{"key":"1188_CR41","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","volume":"79","author":"J Shen","year":"2019","unstructured":"Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res. 2019;79:311\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-1003.","journal-title":"Cancer Res"},{"key":"1188_CR42","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.trecan.2019.06.004","volume":"5","author":"EK Lee","year":"2019","unstructured":"Lee EK, Konstantinopoulos PA. Combined PARP and immune checkpoint inhibition in ovarian cancer. Trends Cancer. 2019;5:524\u20138. https:\/\/doi.org\/10.1016\/j.trecan.2019.06.004.","journal-title":"Trends Cancer"},{"key":"1188_CR43","doi-asserted-by":"publisher","first-page":"175883592098765","DOI":"10.1177\/1758835920987654","volume":"13","author":"V Conteduca","year":"2021","unstructured":"Conteduca V, Poti G, Caroli P, Russi S, Brighi N, Lolli C, et al. Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging. Ther Adv Med Oncol. 2021;13:1758835920987654. https:\/\/doi.org\/10.1177\/1758835920987654.","journal-title":"Ther Adv Med Oncol"},{"key":"1188_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102623","volume":"120","author":"GM Iannantuono","year":"2023","unstructured":"Iannantuono GM, Chandran E, Floudas CS, Choo-Wosoba H, Butera G, Roselli M, et al. Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of clinical trials. Cancer Treat Rev. 2023;120:102623. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102623.","journal-title":"Cancer Treat Rev"},{"key":"1188_CR45","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.clgc.2023.12.011","volume":"22","author":"F Ditonno","year":"2024","unstructured":"Ditonno F, Bianchi A, Malandra S, Porcaro AB, Fantinel E, Negrelli R, et al. PARP Inhibitors in Metastatic Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis of Existing Evidence. Clin Genitourin Cancer. 2024;22:402-12.e17. https:\/\/doi.org\/10.1016\/j.clgc.2023.12.011.","journal-title":"Clin Genitourin Cancer"},{"key":"1188_CR46","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s11523-025-01141-9","volume":"20","author":"G Pinterpe","year":"2025","unstructured":"Pinterpe G, Migliaccio F, Ciccarese C, Pedone RR, Belletto R, Russo P, et al. The impact of uncommon HRR alterations as predictors of efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer: a meta-analysis of randomized controlled trials. Target Oncol. 2025;20:405\u201318. https:\/\/doi.org\/10.1007\/s11523-025-01141-9.","journal-title":"Target Oncol"},{"key":"1188_CR47","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.eururo.2024.12.007","volume":"87","author":"SAA Naqvi","year":"2025","unstructured":"Naqvi SAA, Riaz IB, Bibi A, Khan MA, Imran M, Khakwani KZR, et al. Heterogeneity of the treatment effect with PARP inhibitors in metastatic castration-resistant prostate cancer: a living interactive systematic review and meta-analysis. Eur Urol. 2025;87:626\u201340. https:\/\/doi.org\/10.1016\/j.eururo.2024.12.007.","journal-title":"Eur Urol"},{"key":"1188_CR48","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/bju.16130","volume":"132","author":"RK Sayyid","year":"2023","unstructured":"Sayyid RK, Klaassen Z, Berlin A, Roy S, Brand\u00e3o LR, Bernardino R, et al. Poly (adenosine diphosphate-ribose) polymerase inhibitor combinations in first-line metastatic castrate-resistant prostate cancer setting: a systematic review and meta-analysis. BJU Int. 2023;132:619\u201330. https:\/\/doi.org\/10.1111\/bju.16130.","journal-title":"BJU Int"},{"key":"1188_CR49","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.euo.2023.07.013","volume":"7","author":"C Messina","year":"2024","unstructured":"Messina C, Giunta EF, Signori A, Rebuzzi SE, Banna GL, Maniam A, et al. Combining PARP inhibitors and androgen receptor signalling inhibitors in metastatic prostate cancer: a quantitative synthesis and meta-analysis. Eur Urol Oncol. 2024;7:179\u201388. https:\/\/doi.org\/10.1016\/j.euo.2023.07.013.","journal-title":"Eur Urol Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01188-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01188-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01188-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T16:47:03Z","timestamp":1771692423000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01188-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1188"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01188-8","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SZ, DD, NK, SB, and C-KT declare that they have no conflicts of interest that might be relevant to the contents of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"SZ: Conceptualization, formal analysis, investigation, methodology, writing\u2014original draft. DD: Data curation, investigation, writing\u2014review and editing. NK: Formal analysis, investigation, writing\u2014review and editing. SB: Investigation, writing\u2014review and editing. C-KT: Conceptualization, investigation, supervision, writing\u2014review and editing.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}